{"id":3539,"date":"2018-02-13T16:55:42","date_gmt":"2018-02-13T13:55:42","guid":{"rendered":"https:\/\/umram.bilkent.edu.tr\/?p=3539"},"modified":"2018-09-12T16:56:54","modified_gmt":"2018-09-12T13:56:54","slug":"european-patent-nanoparticle-formulation-containing-farnesylthiosalicyclic-acid","status":"publish","type":"post","link":"https:\/\/umram.bilkent.edu.tr\/index.php\/2018\/02\/13\/european-patent-nanoparticle-formulation-containing-farnesylthiosalicyclic-acid\/","title":{"rendered":"European patent &#8220;NANOPARTICLE FORMULATION CONTAINING FARNESYLTHIOSALICYCLIC ACID&#8221;"},"content":{"rendered":"<p>European patent application (WO2015167408)(PCT\/TR2014\/000248) entitled &#8220;NANOPARTICLE FORMULATION CONTAINING FARNESYLTHIOSALICYCLIC ACID&#8221; has been concluded positively and the registration decision has been finalized. Farnesylthiosalicylic acid (Salirasib, FT A), a new generation antineoplastic agent, is a specific inhibitor of Ras protein, which presents in high rate in most of malignant tumors.The patentable study is a targeted chemotherapy\u00a0 to change the disposition, uptake or efficacy of antineoplastic drugs by providing more damages to tumor cells rather than normal cells. Former UMRAM researcher Taner Demir and UMRAM\u00a0 Professor Kader Karl\u0131 Oguz are among the invention owners. \u00a0Other \u00a0authors \u00a0includes\u00a0 Sibel PEHL\u0130VAN, \u0130mran VURAL, Melike Mut A\u015eKUN, Figen S\u00d6YLEMEZO\u011eLU of Hacettepe University Medical School and Abbas KAFFASHI, Sevda L\u00dcLE, H\u00fcsn\u00fc KO\u015eUCU, Can SARIS\u00d6ZEN.\u00a0<a href=\"https:\/\/www.google.com\/patents\/WO2015167408A1?cl=en%20[1]\" target=\"_blank\" rel=\"noopener\">\u00a0See:\u00a0<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>European patent application (WO2015167408)(PCT\/TR2014\/000248) entitled &#8220;NANOPARTICLE FORMULATION CONTAINING FARNESYLTHIOSALICYCLIC ACID&#8221; has been concluded positively and the registration decision has been finalized. Farnesylthiosalicylic acid (Salirasib, FT A), a new generation antineoplastic agent, is a specific inhibitor of Ras protein, which presents in high rate in most of malignant tumors.The patentable study is a targeted chemotherapy\u00a0 to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3540,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[256],"tags":[],"_links":{"self":[{"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/posts\/3539"}],"collection":[{"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/comments?post=3539"}],"version-history":[{"count":1,"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/posts\/3539\/revisions"}],"predecessor-version":[{"id":3541,"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/posts\/3539\/revisions\/3541"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/media\/3540"}],"wp:attachment":[{"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/media?parent=3539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/categories?post=3539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/umram.bilkent.edu.tr\/index.php\/wp-json\/wp\/v2\/tags?post=3539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}